Skip to main content
Richard Chen on Muck Rack

Richard Chen

Seattle
As seen in: Medium, MSN Philippines, Nature, Wiley Online Library, Business Wire, Frontiers, MDPI, South China Morning Post, Substack, Flipboard and

Get in touch with Richard

Contact Richard, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

China’s ByteDance discovers new scaling law that could sustain AI boom

|
By Richard Chen
| Flipboard
Artificial Intelligence 16 hours ago The only AI glossary you’ll need this year TechCrunch - Natasha Lomas, Romain Dillet, Kyle Wiggers, Lucas Ropek • 16h Artificial intelligence is rewriting the world, and simultaneously inventing a whole new language to describe how it’s doing it.
Open in Who Shared Issue with article?

Private Fund Due Diligence: A Checklist For Reviewing Governing Documents And Operational Controls

|
By Richard Chen
| Nerd's Eye View
Executive Summary For most of our history, the domain of the financial advisor has been helping clients to invest their savings in publicly traded stocks and bonds that create opportunities for long-term growth, in order to achieve clients' retirement and other savings goals.
Open in Who Shared Issue with article?

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer : A Secondary Analysis of the DAPHNe Trial

|
By Paolo Tarantino, Tianyu Li, Esther Ritah Ogayo, Tasnim Rahman, Molly DiLullo, Ashka Patel, Sherif M. El-Refai, Charles Abbott, Bailiang Li, Sean Boyle, Richard Chen, Neelam V. Desai, Laura M. Spring, Nadine Tung, Natalie Sinclair, Meredith Faggen, Michael Constantine, Tari A. King, Ian Krop, Nabihah Tayob, Elizabeth A. Mittendorf, Sara M. Tolaney, Eric P. Winer, Heather A. Parsons, Adrienne G. Waks
| JAMA Oncology Verified
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial Supplement 1. Supplement 2. eFigure 1. REMARK diagram eFigure 2. Swimmer plot of ctDNA status in DAPHNe by level of detection eFigure 3. Boxplot of baseline PPM by pCR and ER status (PPM < 6000 were plotted; patients with undetectable ctDNA are excluded) eTable 1. ctDNA positivity at baseline by clinical variables eTable 2.
Open in Who Shared Issue with article?
See all 97 licensed articles (112 Total)